{"transactions":[{"id":1105433,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T07:00:05.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":1440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":1440,"derivative":{"exercise_price":3.22,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":1440},"source":{"system":"sec-edgar","filing":"0000950170-25-088162","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000095017025088162/ownership.xml","form_type":"4"}},{"id":1472456,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T16:00:05.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":36000,"derivative":{"exercise_price":0.49,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0000950170-24-076187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000095017024076187/ownership.xml","form_type":"4"}},{"id":1854914,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:00:11.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":36000,"derivative":{"exercise_price":2.12,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-23-037285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919123037285/doc4.xml","form_type":"4"}},{"id":2184754,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T19:02:25.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":3380951,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC (\"GP V\") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, \"BCC V\"). Bay City Capital, LLC (\"BCC LLC\") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924322028874/doc4.xml","form_type":"4"}},{"id":2184753,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T19:02:25.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8994,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924322028874/doc4.xml","form_type":"4"}},{"id":2184752,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T19:02:25.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":13060,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."}],"balance_after":8994,"source":{"system":"sec-edgar","filing":"0000899243-22-028874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924322028874/doc4.xml","form_type":"4"}},{"id":2231844,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T16:00:13.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":36000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-22-036932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919122036932/doc4.xml","form_type":"4"}},{"id":2245875,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-03T20:21:19.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":1.07,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-034390","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919122034390/doc4.xml","form_type":"4"}},{"id":2264407,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T16:23:40.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":41006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":41006,"derivative":{"exercise_price":0.56,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":41006},"source":{"system":"sec-edgar","filing":"0000899243-22-018818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924322018818/doc4.xml","form_type":"4"}},{"id":2264406,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-05-19T16:23:40.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":8994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 8,994 restricted stock units (\"RSUs\") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":22054,"source":{"system":"sec-edgar","filing":"0000899243-22-018818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924322018818/doc4.xml","form_type":"4"}},{"id":2503503,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T17:00:16.000Z","date":"2021-11-17","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This stock option was granted to the Reporting Person for serving as the Chair of the Board."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest in equal monthly installments beginning July 1, 2021, when the Reporting Person became the Chair of the Board of the Issuer, until July 1, 2022."}],"balance_after":18000,"derivative":{"exercise_price":3.23,"expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919121065841/doc4.xml","form_type":"4"}},{"id":2650744,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-06-30T18:48:36.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":7728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":7728,"derivative":{"exercise_price":8.12,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":7728},"source":{"system":"sec-edgar","filing":"0001209191-21-044089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919121044089/doc4.xml","form_type":"4"}},{"id":2669126,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T16:35:03.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":40559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.  In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":40559,"derivative":{"exercise_price":8.53,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":40559},"source":{"system":"sec-edgar","filing":"0000899243-21-023866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924321023866/doc4.xml","form_type":"4"}},{"id":2669125,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2021-06-15T16:35:03.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":8060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 8,060 restricted stock units (\"RSUs\") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting.  In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":13060,"source":{"system":"sec-edgar","filing":"0000899243-21-023866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924321023866/doc4.xml","form_type":"4"}},{"id":2691867,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T16:00:20.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":4.93,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919121036507/doc4.xml","form_type":"4"}},{"id":2981884,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2020-11-13T07:05:27.000Z","date":"2020-11-11","kind":"purchase","acquired":true,"shares":5000,"price":12.07,"value":60350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 per share to $12.10 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-20-030917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030917/doc4.xml","form_type":"4"}},{"id":2993318,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":3688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9587},"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993317,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-3 Preferred Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":7475,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. (\"Co-Investment V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC (\"Management V\").  Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V.  Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19432},"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993316,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-3 Preferred Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":392367,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Bay City Capital Fund V, L.P. (\"Fund V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC (\"Management V\").  Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V.  Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1020036},"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993315,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-09-25","kind":"grant","acquired":true,"shares":3688,"price":27.11,"value":99981.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":3688,"derivative":{"underlying":"Common Stock","underlying_shares":9587},"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993314,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":19432,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. (\"Co-Investment V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC (\"Management V\").  Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V.  Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":19432,"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993313,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":1020036,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Bay City Capital Fund V, L.P. (\"Fund V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC (\"Management V\").  Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V.  Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":1020036,"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":2993312,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T20:00:25.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":9587,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":9587,"source":{"system":"sec-edgar","filing":"0000899243-20-030416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320030416/doc4.xml","form_type":"4"}},{"id":3127811,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T16:16:36.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":14013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director.  In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":14013,"derivative":{"exercise_price":17.55,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":14013},"source":{"system":"sec-edgar","filing":"0000899243-20-014898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320014898/doc4.xml","form_type":"4"}},{"id":3209461,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":15457,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in three equal installments on March 16, 2021, 2022 and 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are held directly by Bay City Capital LLC (\"BCC LLC\") and represent stock options granted to Dr. Goldfischer and transferred to BCC LLC pursuant to an agreement between Dr. Goldfischer and BCC LLC. Dr. Goldfischer disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Goldfischer is the beneficial owner of such shares."}],"balance_after":15457,"derivative":{"exercise_price":16,"expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":15457},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209460,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":16103,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2555},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209459,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":845008,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":134148},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209458,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":61378,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9741},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209457,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":3220915,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":511335},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209456,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5372,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":852},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209455,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":281878,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44749},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209454,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":13148,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":703380,"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209453,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":690232,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":690232,"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3497676,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-07T16:28:57.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":17633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on May 31, 2020, subject to Reporting Person's continued service as a director.  In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":17633,"derivative":{"exercise_price":13.74,"expiration_date":"2029-05-30","underlying":"Common Stock","underlying_shares":17633},"source":{"system":"sec-edgar","filing":"0000899243-19-016018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924319016018/doc4.xml","form_type":"4"}},{"id":3668966,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T20:21:09.000Z","date":"2019-02-07","kind":"exercise","acquired":false,"shares":9340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":9340},"source":{"system":"sec-edgar","filing":"0001333277-19-000034","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000034/edgar.xml","form_type":"4"}},{"id":3668965,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T20:21:09.000Z","date":"2019-02-07","kind":"exercise","acquired":false,"shares":2335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":2335},"source":{"system":"sec-edgar","filing":"0001333277-19-000034","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000034/edgar.xml","form_type":"4"}},{"id":3668964,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T20:21:09.000Z","date":"2019-02-07","kind":"sale","acquired":false,"shares":11675,"price":9.0217,"value":105328.3475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive.  The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001333277-19-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000034/edgar.xml","form_type":"4"}},{"id":3668963,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T20:21:09.000Z","date":"2019-02-07","kind":"exercise","acquired":true,"shares":9340,"price":5.5,"value":51370.0,"ownership":{"direct":true},"balance_after":11675,"source":{"system":"sec-edgar","filing":"0001333277-19-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000034/edgar.xml","form_type":"4"}},{"id":3668962,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T20:21:09.000Z","date":"2019-02-07","kind":"exercise","acquired":true,"shares":2335,"price":5,"value":11675.0,"ownership":{"direct":true},"balance_after":2335,"source":{"system":"sec-edgar","filing":"0001333277-19-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000034/edgar.xml","form_type":"4"}},{"id":3681652,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-31T17:20:41.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":27705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2019."}],"balance_after":27705,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":27705},"source":{"system":"sec-edgar","filing":"0001333277-19-000020","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327719000020/edgar.xml","form_type":"4"}},{"id":3913066,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-31T16:24:42.000Z","date":"2018-05-18","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full."}],"balance_after":12500,"derivative":{"exercise_price":17,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-034362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919118034362/doc4.xml","form_type":"4"}},{"id":3984284,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"exercise","acquired":false,"shares":5660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/12 of the underlying shares monthly from June 1, 2017."}],"balance_after":9340,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":5660},"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":3984283,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"exercise","acquired":false,"shares":2870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2024-01-05","underlying":"Common Stock","underlying_shares":2870},"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":3984282,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"exercise","acquired":false,"shares":6470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-10-30","underlying":"Common Stock","underlying_shares":6470},"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":3984281,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"sale","acquired":false,"shares":15000,"price":13.025,"value":195375.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive.  The reporting person undertakes tp provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":3984280,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"exercise","acquired":true,"shares":5660,"price":5.5,"value":31130.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":3984279,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T16:56:49.000Z","date":"2018-03-22","kind":"exercise","acquired":true,"shares":9340,"price":5,"value":46700.0,"ownership":{"direct":true},"balance_after":9340,"source":{"system":"sec-edgar","filing":"0001333277-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000035/edgar.xml","form_type":"4"}},{"id":4088735,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-26T17:00:33.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018."}],"balance_after":16000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001333277-18-000020","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000133327718000020/edgar.xml","form_type":"4"}},{"id":4171742,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-06T20:45:21.000Z","date":"2017-11-02","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.97,"expiration_date":"2025-06-23","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-059524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117059524/doc4.xml","form_type":"4"}},{"id":4171741,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-06T20:45:21.000Z","date":"2017-11-02","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.72,"expiration_date":"2026-06-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-059524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117059524/doc4.xml","form_type":"4"}},{"id":4171740,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T20:45:21.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":18000,"price":8.66,"value":155880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $8.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-059524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117059524/doc4.xml","form_type":"4"}},{"id":4171739,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T20:45:21.000Z","date":"2017-11-02","kind":"exercise","acquired":true,"shares":9000,"price":2.97,"value":26730.0,"ownership":{"direct":true},"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001209191-17-059524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117059524/doc4.xml","form_type":"4"}},{"id":4171738,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T20:45:21.000Z","date":"2017-11-02","kind":"exercise","acquired":true,"shares":9000,"price":1.72,"value":15480.0,"ownership":{"direct":true},"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001209191-17-059524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117059524/doc4.xml","form_type":"4"}},{"id":4201798,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-26T09:35:09.000Z","date":"2017-09-22","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person."}],"balance_after":7500,"derivative":{"exercise_price":7.47,"expiration_date":"2027-09-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-17-053899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117053899/doc4.xml","form_type":"4"}},{"id":4269585,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-30T14:55:05.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017."}],"balance_after":15000,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001042074-17-000016","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000104207417000016/primary_doc.xml","form_type":"4"}},{"id":4272830,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-26T13:54:59.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 22, 2017, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on June 22, 2018 and, in the event of a change in control of the Company, the vesting will accelerate in full."}],"balance_after":12500,"derivative":{"exercise_price":13.65,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-17-041810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117041810/doc4.xml","form_type":"4"}},{"id":4300353,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-31T15:31:53.000Z","date":"2017-05-25","kind":"sale","acquired":false,"shares":97,"price":4.85,"value":470.45,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. (\"Co-Investment IV\"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-17-008246","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000117911017008246/edgar.xml","form_type":"4/A","original_submission_date":"2017-05-26"}},{"id":4300352,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-31T15:31:53.000Z","date":"2017-05-25","kind":"sale","acquired":false,"shares":4571,"price":4.85,"value":22169.35,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by Bay City Capital Fund IV, L.P. (\"Fund IV\"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC (\"BCC\"), the manager of Bay City Capital Management IV LLC (\"Management IV\"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-17-008246","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000117911017008246/edgar.xml","form_type":"4/A","original_submission_date":"2017-05-26"}},{"id":4303594,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-26T15:10:52.000Z","date":"2017-05-25","kind":"sale","acquired":true,"shares":97,"price":4.85,"value":470.45,"ownership":{"direct":false,"nature":"See footnote note (2)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. (\"Co-Investment IV\"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-17-008065","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000117911017008065/edgar.xml","form_type":"4"}},{"id":4303593,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-26T15:10:52.000Z","date":"2017-05-25","kind":"sale","acquired":true,"shares":4571,"price":4.85,"value":22169.35,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by Bay City Capital Fund IV, L.P. (\"Fund IV\"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC (\"BCC\"), the manager of Bay City Capital Management IV LLC (\"Management IV\"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-17-008065","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000117911017008065/edgar.xml","form_type":"4"}},{"id":4457768,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Option (Right to Buy)","published_at":"2017-02-10T16:45:31.000Z","date":"2017-02-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month over the three (3) year period measured from the date shown."}],"balance_after":35000,"derivative":{"exercise_price":7.12,"exercise_date":"2017-02-08","expiration_date":"2027-02-08","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-17-009584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000120919117009584/doc4.xml","form_type":"4"}}]}